Quarterly report · Q2
2372.TEDINET S100S4U1
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥18.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥790m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥36.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥35.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥30.4bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥23.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥13.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥803m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥17m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥740m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.22 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.56 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.17 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥210.06 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥163.91 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥542m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥764m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥844m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥885m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥23m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥610m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥66m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥943m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥533m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥409m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥35m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥490m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥68m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥118m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥673m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥594m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥592m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥184m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥88m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥978m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥528m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥28m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥61m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥601m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 540
| Item | Context | Value | Unit |
|---|---|---|---|
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05352 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 23720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社アイロムグループ | |
| Filer name in english | FilingDateInstant | I'rom Group Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（プライム市場） | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)森 豊隆 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | TSIM SHA TSUI, KOWLOON HONG KONG | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)森 利恵 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | TSIM SHA TSUI, KOWLOON HONG KONG | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行㈱（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区浜松町２－11－３ | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)セントラル短資㈱ | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋本石町３－３－14 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |